Systemic bevacizumab (Avastin®) Therapy for exudative neovascular age-related macular degeneration. The BEAT-AMD-study.
Résumé
Double-blinded, randomised, prospective, pilot-study to determine the effect of systemic bevacizumab therapy.
Origine | Fichiers produits par l'(les) auteur(s) |
---|
Loading...